Pharmaceutical firms compete on formulations even for OTC drugs, differentiating products through ease of taking them
- Input
- 2026-11-12 16:08:08
- Updated
- 2026-11-12 16:08:08

According to industry sources on the 12th, diversifying OTC formulations is also a strategy for maintaining the competitiveness of established brands while attracting new consumer groups. The approach expands the market by adding products under a single brand to suit different purposes and lifestyles.
Hyundai Pharmaceutical’s hair-loss treatment brand Minoxyl caters to consumer demand with a range of topical and oral products. Its lineup includes Minoxyl Foam, Minoxyl Gel, which is applied to specific areas, Minoxyl Solution, which is sprayed directly onto the scalp, and Minoxyl S Capsules, an oral hair-loss treatment.
Minoxyl Foam, in particular, is promoted as easy to apply to the scalp and less likely to run because of its foam formulation. Another feature is that it does not leave crystals or a white cast after use. Hyundai Pharmaceutical continues to run digital ads highlighting the features of each formulation as well as its efficacy, with clinical tests involving Koreans finding a 92.9% improvement rate in hair-loss symptoms.
In the cold medicine market, Dong-A Pharmaceutical has moved to expand the range of formulations under its Panpyrin brand. It recently launched three varieties of Panpyrin Time Ibuprofen, adding a liquid stick formulation. The company says these are the first liquid stick cold medicines in Korea with ibuprofen as their main ingredient.
The company has diversified its lineup by adding a liquid form to its existing flagship product, Panpyrin Q, the tea-style Panpyrin Time Night Flu Dry Syrup and the powder-form Panpyrin Time Powder, offering products suited to different ways of taking medicine. The products target consumers who prefer options that are easy to carry and take.
Yuhan Corporation offers products with different ingredients and formulations under Magby, its brand of OTC magnesium medicines. Magby Max is a high-dose soft capsule containing 350 mg of magnesium oxide (equivalent to 211 mg of magnesium) per two capsules daily. Magby Speed, by contrast, is a liquid product containing 1,200 mg of magnesium glycerophosphate, an organic magnesium salt (equivalent to 150 mg of magnesium), and can be taken without water. The product line gives consumers more options by varying the dosage and form even within the same magnesium range.
The pharmaceutical industry sees competition in the OTC market shifting beyond ingredients and efficacy to the user experience. That is because purchasing decisions are influenced not only by a product’s efficacy but also by how easily consumers can use it in their daily lives.
An industry official said, “Because consumers choose OTC medicines themselves, ease of taking them and the conditions in which they are used are also important competitive factors,” adding, “Pharmaceutical companies will continue to pursue strategies to diversify formulations and product offerings based on their established brands.”
[email protected] Jung Sang-hee Reporter